Page last updated: 2024-12-11
ipamorelin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9831659 |
| CHEMBL ID | 58547 |
| SCHEMBL ID | 183305 |
| SCHEMBL ID | 8169698 |
| MeSH ID | M0295513 |
Synonyms (23)
| Synonym |
|---|
| ipamorelin [inn] |
| aib-his-2nal-phe-lys-nh2 |
| 170851-70-4 |
| y9m3s784z6 , |
| unii-y9m3s784z6 |
| 2-methylalanyl-l-histidyl-3-(2-naphthyl)-d-alanyl-d-phenylalanyl-l-lysinamide. |
| 2-methylalanyl-l-histidyl-3-(2-naphthyl)-d-alanyl-d-phenylalanyl-l-lysinamide |
| ipamorelin , |
| NCGC00167295-01 |
| nnc-26-0161 |
| aib-his-d-2-nal-d-phe-lys-nh2 |
| nnc-260161 |
| CHEMBL58547 |
| nnc 26-0161 |
| ipamorelin [who-dd] |
| SCHEMBL183305 |
| SCHEMBL8169698 |
| AKOS030573449 |
| DB12370 |
| AMY25371 |
| ipamorelin acetate |
| AS-56185 |
| VGA85170 |
Research Excerpts
Overview
Ipamorelin is a new and potent synthetic pentapeptide. It has distinct and specific growth hormone (GH)-releasing properties.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo." | ( Ipamorelin, the first selective growth hormone secretagogue. Andersen, PH; Ankersen, M; Hansen, BS; Johansen, NL; Madsen, K; Raun, K; Thøgersen, H, 1998) | 2.46 |
| "Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties. " | ( Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Andreassen, TT; Flyvbjerg, A; Johansen, PB; Nowak, J; Orskov, H; Skjaerbaek, C; Wilken, M, 1999) | 3.19 |
Bioavailability
NNC 26-0235 and ipamorelin were able to increase basal GH level by more than 10-fold after oral administration of a dose of 1.
| Excerpt | Reference | Relevance |
|---|---|---|
| " After intranasal application, the bioavailability of ipamorelin was estimated at approximately 20%." | ( Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Andersen, JV; Hansen, KT; Johansen, NL; Johansen, PB, 1998) | 0.84 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound." | ( Novel orally active growth hormone secretagogues. Andersen, PH; Ankersen, M; Hansen, BS; Hansen, TK; Johansen, NL; Lau, J; Lundt, BF; Madsen, K; Nielsen, KK; Peschke, B; Raun, K; Thøgersen, H, 1998) | 0.3 |
| "01-1 mg/kg), growth hormone-releasing peptide (GHRP)-6 (20 microg/kg), or vehicle (saline) were administered via intravenous bolus infusion after a single dosing or a 2-day repetitive dosing regimen (four doses a day at 3-h intervals)." | ( Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Greenwood-Van Meerveld, B; Mann, W; Nelson, R; Venkova, K, 2009) | 0.73 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 0.7943 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 0.7943 | 4.4668 | 18.3916 | 35.4813 | AID2107 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0708 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID209311 | Compound was tested for potency against GH release iv administration in swine | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Novel orally active growth hormone secretagogues. |
| AID61090 | Basal GH release was measured after 0.5 mg/kg iv administration into Beagle dogs | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID176149 | Tested in vivo for GH-releasing potency against anesthetized male rats | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID10685 | Area under curve was measured after i.v. administration into Beagle dog. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID18437 | Oral bioavailability in dog (Beagle) | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID159530 | Release of growth hormone at single iv dose of 50 nmol/kg in pigs | 2001 | Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14 | Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. |
| AID195921 | Tested in vitro for GH-releasing potency against rat pituitary cells. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID13883 | Maximum Concentration was measured after po administration into Beagle dog. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID159423 | Effective dose required for release of GH from pigs in vivo | 2001 | Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14 | Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. |
| AID195930 | Efficacy was determined as percent of GHRP-6 in rat pituitary cell assay tested in vitro | 2001 | Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14 | Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. |
| AID209314 | Compound was tested for efficacy against GH release iv administration in swine | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Novel orally active growth hormone secretagogues. |
| AID61092 | Basal GH release was measured after 2.7 mg/kg po administration into Beagle dogs | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID13881 | Maximum Concentration was measured after iv administration into Beagle dog. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID10688 | Area under curve was measured after po administration into Beagle dog. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID195923 | Concentration required for GH release from isolated pituitary cells of rat tested in vitro | 2001 | Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14 | Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. |
| AID209313 | Compound was tested for GH-releasing potency against female Danish slaughter swine. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID209310 | Compound was tested for GH-releasing potency against female Danish slaughter swine. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID179870 | Tested in vivo for GH-releasing potency against anesthetized male rats | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| AID195929 | Tested in vitro for GH-releasing potency against rat pituitary cells. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 77.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (77.64) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (7.41%) | 5.53% |
| Reviews | 2 (7.41%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (85.19%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||